HER-2: A possible target for therapy of metastatic urinary bladder carcinoma
2002 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 41, no 3, 282-288 p.Article in journal (Refereed) Published
Human epidermal growth factor receptor 2, HER-2, is overexpressed in various tumours, e.g. breast- and bladder tumours. The aim of this study was to predict the potential use of HER-2 receptors as targets in systemic treatment of disseminated bladder tumours. HER-2 expression was assessed in bladder carcinoma metastases and the corresponding primary tumours, and subsequently compared with the EGFR expression. HER-2 and EGFR expression was analysed by immunohistochemistry in formalin-fixed, paraffin-embedded tissues from 21 patients with metastatic bladder carcinoma. HER-2 was overexpressed in 81% of the primary tumours and in 67% of the metastases. All HER-2-positive metastases were from HER-2-positive primary tumours. The results for EG FR were 71% of both primary and metastases-positive tumours. In 90% of the primary tumours and 86% of the metastases, at least one of the receptors was overexpressed. These results suggest that HER-2 targeted therapy can be considered as an alternative or a complement to other modalities in the treatment of metastatic urinary bladder carcinoma.
Place, publisher, year, edition, pages
2002. Vol. 41, no 3, 282-288 p.
Radiology, Nuclear Medicine and Medical Imaging Urology and Nephrology
IdentifiersURN: urn:nbn:se:uu:diva-64303DOI: 10.1080/02841860260088836PubMedID: 12195748OAI: oai:DiVA.org:uu-64303DiVA: diva2:92214